• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOSS alert in real time by email

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects.

    Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownership stakes.

    It is essential to note that while insider sales can occur for various reasons and may not always signify negative sentiment, insider purchases are generally considered more significant as they demonstrate confidence in the company's future performance.

    Further, on 2024-06-21, Chief Commercial Officer Robert Paul Jr. Smith made a notable purchase of $15,050 worth of shares, acquiring 25,000 units at $0.60. Insider purchases by senior executives, such as the Chief Commercial Officer, can be viewed positively by investors, indicating belief in the company's growth potential.

    Reviewing the data from these transactions, one interesting pattern emerges with the insider purchases by Giraudo Bryan and Smith Robert Paul Jr. on the same date, indicating a potential alignment in positive outlook regarding Gossamer Bio Inc.'s future trajectory.

    Additionally, considering the pricing of the recent insider purchases, particularly Giraudo's acquisition at $0.59 per share and Smith's buy at $0.60 per share, it reflects a belief by the insiders that the current stock price may present a buying opportunity or be undervalued based on their internal assessments of the company's intrinsic value.

    Comparing these insider transactions with the filings by Daniel Thomas O, Cox Russell J., Milligan Sandra, and Quisel John D. on 2024-06-07, where no significant purchase activity was reported, it seems that the recent insider purchases by Giraudo and Smith stand out as pivotal events in terms of signaling positive sentiment within the company.

    Given the context of these insider transactions and the patterns observed, investors may interpret the recent purchase by Giraudo Bryan and Chief Commercial Officer Robert Paul Jr. Smith as encouraging signals regarding Gossamer Bio Inc.'s future prospects. These insider actions suggest a sense of confidence and belief in the company's potential growth trajectory, which could potentially influence investor sentiment positively.

    While one should not base investment decisions solely on insider transactions, they can serve as valuable indicators when combined with comprehensive fundamental and technical analysis. Investors are advised to conduct thorough research and consider various factors before making any investment decisions.

    Get the next $GOSS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GOSS

    DatePrice TargetRatingAnalyst
    3/23/2026Overweight → Neutral
    Cantor Fitzgerald
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    1/28/2026$9.00Overweight
    Barclays
    9/10/2025$9.00Neutral → Buy
    UBS
    7/14/2025$11.00Sector Outperform
    Scotiabank
    6/25/2024$9.00Outperform
    Oppenheimer
    More analyst ratings

    $GOSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Gossamer Bio from Overweight to Neutral

    3/23/26 8:26:50 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00

    2/24/26 8:01:18 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Barclays with a new price target

    Barclays downgraded Gossamer Bio from Overweight to Equal Weight and set a new price target of $0.30

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Aranda Richard

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    3/20/26 4:22:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Peterson Caryn

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    3/20/26 4:20:55 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Smith Robert Paul Jr

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    3/20/26 4:19:57 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    SEC Filings

    View All

    Gossamer Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Gossamer Bio, Inc. (0001728117) (Filer)

    6/2/26 8:00:32 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Gossamer Bio Inc.

    PRE 14A - Gossamer Bio, Inc. (0001728117) (Filer)

    5/18/26 7:08:38 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Gossamer Bio Inc.

    DEFA14A - Gossamer Bio, Inc. (0001728117) (Filer)

    5/18/26 7:07:40 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

    Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the "Exchange Offer") to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the "Existing Convertible Notes") for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes due 2030 (the "New Convertible Notes"), (ii) up to

    6/3/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

    Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has extended the early tender date (as extended, the "Extended Early Tender Date") until 5:00 p.m., New York City time, on June 2, 2026 with respect to its previously announced exchange offer (the "Exchange Offer") and consent solicitation (the "Consent Solicitation") to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the "Existing Convertible Notes") for a

    6/2/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

    Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has commenced an exchange offer (the "Exchange Offer") to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the "Existing Convertible Notes") for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes due 2030 (the "New Convertible Notes"), (ii) up to 317,647,058 shares of its common stock (th

    5/18/26 7:05:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Hasnain Faheem bought $250,282 worth of shares (372,000 units at $0.67) (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    6/24/24 5:52:18 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO/CFO Giraudo Bryan bought $59,110 worth of shares (100,000 units at $0.59) (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    6/20/24 8:21:38 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Leadership Updates

    Live Leadership Updates

    View All

    Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

    - Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer. "We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company's history," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.

    12/5/23 7:01:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. "Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quise

    11/29/23 7:01:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine. In this role, he partnered with the development and commercial teams to lead pre-launch and launch activities of several approved PAH products, including Uptravi® (selixpag),

    10/3/23 4:08:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Financials

    Live finance-specific insights

    View All

    Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

    Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the "Exchange Offer") to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the "Existing Convertible Notes") for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes due 2030 (the "New Convertible Notes"), (ii) up to

    6/3/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

    - FDA Confirms In-Person Pre-NDA Type B Meeting in Mid-June - - Positive PROSERA CT FRI Results Demonstrated Multiple Statistically Significant Treatment Effects, Including Novel Signals Correlated with Clinical Outcomes - - Gossamer Announces Commencement of Exchange Offer and Consent Solicitation for Outstanding 5.00% Convertible Senior Notes Due 2027 - - Cash, cash equivalents and marketable securities totaled $99 million as of March 31 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with in

    5/18/26 7:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2026 financial results on Monday, May 18, 2026. In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 8:00 a.m. ET on Monday, May 18, 2026, to discuss the Company's financial results and provide a corporate update. Domestic Dial-in Number: 1-800-715-9871 International Dial-in Number: 1-646-307-1963

    5/15/26 7:01:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 4:40:26 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    11/12/24 9:55:14 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

    SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

    8/2/24 6:30:57 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOSS
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care